Fermenta Biotech Ltd · BSE:FERMENTA
Fermenta Biotech — Shareholder Meeting (August 2025)
19 slides from Fermenta Biotech's shareholder meeting presentation, Aug 12, 2025
Slide 1: BSE filing cover letter for AGM presentation
Fermenta Biotech Limited CIN: L99999MH1951PLC008485 Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India. Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com, Website. : www.fermentabiotech.com Ref: F.No.:908 August 12, 2025 Corporat
Slide 2: 73rd Annual General Meeting of Shareholders
73rd Annual General Meeting of Shareholders 12 August 2025
Slide 3: 2024-25 was a year of financial recovery and breakthrough innovation
2024-25 was a year of financial recovery and breakthrough innovation Investor presentation | 2
Slide 4: Talking Points
Talking Points Strategic Realignment Delivers Results Refocused strategy on execution, efficiency, and innovation after navigating significant post-pandemic headwinds over the past two years Robust Financial Turnaround Consolidated revenue surged to ₹481 crore, up 39% from ₹347 crore in FY24 Restore
Slide 5: Recent Timeline
Recent Timeline Manufacturing & technology breakthroughs ₹ 481 Cr RECENT Backward integration & strategic growth Human nutrition innovations ₹ 407 Cr ₹ 347 Cr FY Revenue Plant-source Vitamin D3 ₹ 305 Cr Global recognition 2025 Completed validation batches for 2022 spray dried variant of Vitamin D3 1
Slide 6: The Opportunity
The Opportunity Leverage Fermenta’s strengths towards meeting evolving consumer needs and regulatory requirements across diverse markets India Global Innovation Drivers ✓ Preventive health ✓ Nutritional ✓ Nutrigenomics awareness supplements ✓ Natural/organic solutions ✓ Growing middle class ✓ Aging
Slide 7: Strategy Map
Strategy Map Our Mission Global nutritional wellness while creating value for society, customers, and investors. Financial Financial Performance and Drive consistent, industry-leading financial results Investor Value Optimize asset value to maximize investor returns Ensure sustainable growth through
Slide 8: Manufacturing and R&D
Manufacturing and R&D Enzymes and APIs including Vitamin D3 Customized premix plant Multiple global regulatory certifications Kullu Dedicated Vitamin D3 with backward Himachal Pradesh integration for cholesterol Multiple global regulatory Collaboration with toll certifications manufacturer for Vitam
Slide 9: Strategic Partnership Ecosystem
Strategic Partnership Ecosystem The Collaboration Strategic Value Global healthcare company Vitamin D awareness campaigns Extends our reach to healthcare Abbott specializing in diagnostics, Print and audiovisual educational materials professionals and patients medical devices, and nutrition Premier
Slide 10: FBL Certifications
FBL Certifications Comprehensive certifications demonstrate our commitment to meet diverse customer needs and global standards of quality, safety, sustainability, and ethical production. Adherence to stringent guidelines for GMP approval for dietary supplements European pharmaceutical markets Confir
Slide 11: R&D Focus Areas & Achievements
R&D Focus Areas & Achievements Focus Key Achievements Future Directions Calcifediol commercialization API Product pipelines Commercialized 11 products including Vitamin K1, Cholesterol, Lanolin derivatives VITADEE Green Process improvement Cost optimization for Vitamin K1 process VITADEE SD (Spray D
Slide 12: Strategic Portfolio for Future Growth
Strategic Portfolio for Future Growth Spray-Dried Vitamin D3 VITADEE Green Vitamin K1 Customized Premixes ✓ Patented 100,000 IU/g ✓ Plant-based Vitamin D3 with ✓ Strategic expansion into ✓ Equipped with advanced instrumentation pharmaceutical-grade technology clean-label for vegan supplement essenti
Slide 13: Globally Diversified Revenue with Balanced Customer Base
Globally Diversified Revenue with Balanced Customer Base Resilient Revenue Streams Geographical Revenue Mix Excl. Value Unlocking % of revenue from largest customer 9% % of revenue from top 5 customers 25% FY22 35% 25% 14% 26% % of revenue from top 10 customers 38% FY23 39% 21% 15% 24% % of revenues
Slide 14: Fermenta's Value Proposition
Fermenta’s Value Proposition Society Contribute to global health and preventive care through nutritional ingredients Support life productivity across human and animal populations Address environmental challenges with custom and green chemistry solutions Best-in-class, science-backed Market leadershi
Slide 15: Key Numbers
Key Numbers A year of Recovery, Debt Reduction & Operational Efficiency (₹ Crore) (₹ Crore) 481 359 43 117 105 41 Revenue 407 Cash flow from scales new 386 operations 63 heights 347 193 236 210 70 122 Gross Fixed Assets 205 EBITDA Rebounds on 90 154 39 Operational 26 217 Efficiency Debt Reduction: A
Slide 16: Revenue Mix (Consolidated)
Revenue Mix (Consolidated) (₹ Crore) FY22 FY23 FY24 FY25 Nutrition Business 350 248 217 350 6% 9% 13% 18% Vitamin D3 - Human Nutrition 224 163 141 216 8% 4% 6% Others Vitamin D3 - Animal Nutrition 79 37 38 94 12 % 6% 14% 11% Others 47 48 39 40 13% 8% D3 – Animal 19 % 14% Other Business 33 40 46 67 1
Slide 17: Financials
Financials Disciplined Execution Drives Financial Turnaround and Sustainable Growth Income Statement ₹ Crore Balance Sheet ₹ Crore Cash Flow ₹ Crore Total expenses grew at less than half the rate Our disciplined financial stewardship cut Prudent working capital deployment of revenue growth, translat
Slide 18: Takeaway
Takeaway Leadership Position Among top 3 global Vitamin D3 manufacturers with exclusive position in India, serving 350+ customers across 60+ countries Innovation & Manufacturing Excellence 70+ years expertise with 100+ scientists driving innovation in premium nutritional ingredients backed by state-
Slide 19: Thank you
Thank you Contact info@fermentabiotech.com Fermenta Biotech Ltd